RT Journal Article
SR Electronic
T1 Translating Subphenotypes of Newly Diagnosed Type 2 Diabetes from Cohort Studies to Electronic Health Records in the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.08.24315128
DO 10.1101/2024.10.08.24315128
A1 Li, Zhongyu
A1 Liu, Star
A1 Ho, Joyce C.
A1 Narayan, K.M. Venkat
A1 Ali, Mohammed K.
A1 Varghese, Jithin Sam
YR 2024
UL http://medrxiv.org/content/early/2024/10/11/2024.10.08.24315128.abstract
AB Novel subphenotypes of type 2 diabetes mellitus (T2DM) are associated with differences in response to treatment and risk of complications. The most widely replicated approach identified four subphenotypes (severe insulin-deficient diabetes [SIDD], severe insulin-resistant diabetes [SIRD], mild obesity-related diabetes [MOD], and mild age-related diabetes [MARD]). However, the widespread clinical application of this model is hindered by the limited availability of fasting insulin and glucose measurements in routine clinical settings. To address this, we pooled data of adults (≥18 years) with newly diagnosed T2DM from six cohort studies (n = 3,377) to perform de novo clustering and developed classification algorithms for each of the four subphenotypes using nine variables routinely collected in electronic health records (EHRs). After operationalizing the classification algorithms on the Epic Cosmos Research Platform, we identified that among the 727,076 newly diagnosed diabetes cases, 21.6% were classified as SIDD, 23.8% as MOD, and 40.9% as MARD. Individuals classified as SIDD were more likely to receive insulin and incretin mimetics treatment and had higher risks for microvascular complications (retinopathy, neuropathy, nephropathy). Our findings underscore the heterogeneity in newly diagnosed T2DM and validated T2DM subphenotypes in routine EHR systems. This offers possibilities for the subsequent development of treatment strategies tailored to subphenotypes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We were exempt from ethical approval for analysis of secondary datasets. All participants of cohort studies and trials gave written informed consent before participation. Epic Cosmos data was HIPAA-limited and expertly de-identified.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe code for the analysis is available on https://github.com/jvargh7/diabetes_endotypes_cohorts. Data for the National Institutes of Health funded cohort studies are available for request from the NIDDK Central Repository (NIDDK-CR; https://repository.niddk.nih.gov) and NHLBI Biolincc (https://biolincc.nhlbi.nih.gov/home/) to registered users. Epic Cosmos access is available through institutional representatives of participating institutions and the Epic Cosmos team after completing certification requirements.